CytomX Total Cash From Operating Activities from 2010 to 2024
| CTMX Stock | USD 4.47 0.66 12.87% |
Total Cash From Operating Activities | First Reported 2014-09-30 | Previous Quarter -18.2 M | Current Value -22 M | Quarterly Volatility 40.3 M |
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many exotic indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0299 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
CytomX | Total Cash From Operating Activities |
Latest CytomX Therapeutics' Total Cash From Operating Activities Growth Pattern
Below is the plot of the Total Cash From Operating Activities of CytomX Therapeutics over the last few years. It is CytomX Therapeutics' Total Cash From Operating Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Cash From Operating Activities | 10 Years Trend |
|
Total Cash From Operating Activities |
| Timeline |
CytomX Total Cash From Operating Activities Regression Statistics
| Arithmetic Mean | (27,275,550) | |
| Geometric Mean | 26,854,450 | |
| Coefficient Of Variation | (273.26) | |
| Mean Deviation | 52,209,920 | |
| Median | (8,008,000) | |
| Standard Deviation | 74,533,302 | |
| Sample Variance | 5555.2T | |
| Range | 310.9M | |
| R-Value | (0.42) | |
| Mean Square Error | 4946.5T | |
| R-Squared | 0.17 | |
| Significance | 0.12 | |
| Slope | (6,935,638) | |
| Total Sum of Squares | 77773T |
CytomX Total Cash From Operating Activities History
About CytomX Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include CytomX Therapeutics income statement, its balance sheet, and the statement of cash flows. CytomX Therapeutics investors use historical funamental indicators, such as CytomX Therapeutics's Total Cash From Operating Activities, to determine how well the company is positioned to perform in the future. Although CytomX Therapeutics investors may use each financial statement separately, they are all related. The changes in CytomX Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CytomX Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CytomX Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Cash From Operating Activities | -56 M | -53.2 M |
Pair Trading with CytomX Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with CytomX Stock
| 0.81 | VKTX | Viking Therapeutics | PairCorr |
Moving against CytomX Stock
| 0.57 | OVID | Ovid Therapeutics Financial Report 3rd of May 2024 | PairCorr |
The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of CytomX Therapeutics Correlation against competitors. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.